Skip to main content
Mega Genomics Limited logo

Mega Genomics Limited — Investor Relations & Filings

Ticker · 6667 HKEX Professional, scientific and technical activities
Open in API
Filings indexed 317 across all filing types
Latest filing 2026-02-04 Interim / Quarterly Rep…
Country HK Hong Kong
Listing HKEX 6667

About Mega Genomics Limited

https://www.megagenomics.cn

Mega Genomics Limited operates as a genetic testing platform company focused on providing consumer genetic testing and cancer screening services. The core business involves delivering comprehensive genetic analysis solutions to the consumer market. Key product offerings include advanced sequencing packages such as Personal Whole Genome Sequencing, which analyzes over 700,000 genetic loci to assess disease risk and provide pharmacogenomic recommendations. Additionally, the company offers Adult and Children's Whole Exome Sequencing packages, which analyze over 180,000 key exome regions to evaluate risks for high-risk diseases, hereditary cancers, and complex genetic disorders, alongside personalized guidance on drug efficacy, nutrition, and fitness.

Recent filings

Filing Released Lang Actions
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2025
Interim / Quarterly Report Classification · 1% confidence The document is titled 'INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2025' for Mega Genomics Limited. It contains detailed unaudited condensed consolidated financial statements, including profit or loss, revenue breakdowns, and management discussion and analysis (MDA) for the six-month period. As it provides comprehensive financial data for an interim period rather than just a summary or an announcement of a report, it is classified as an Interim/Quarterly Report. H1 2025
2026-02-04 English
ANNUAL REPORT 2024
Annual Report Classification · 1% confidence The document contains a table of contents explicitly listing sections such as 'Chairperson's Report', 'Management Discussion and Analysis', 'Directors' Report', 'Independent Auditor's Report', and 'Consolidated Statement of Financial Position'. It also includes a 'Definitions' section that references 'this annual report'. The structure and content are characteristic of a comprehensive annual financial report. FY 2025
2026-02-04 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 JANUARY 2026
Share Issue/Capital Change Classification · 1% confidence The document is a 'Monthly Return for Equity Issuer' filed with the Hong Kong Stock Exchange (HKEX). This is a standard regulatory filing required by the HKEX Listing Rules (specifically Rule 13.25A) to report monthly movements in securities, share capital, and public float. Since it is a recurring regulatory disclosure of share capital movements rather than a specific corporate event like a dividend announcement or a major shareholding notification, it falls under the 'Regulatory Filings' category.
2026-02-02 English
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2024
Annual Report Classification · 1% confidence The document is titled 'ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2024' and is issued by Mega Genomics Limited. It contains detailed financial highlights, a management discussion and analysis (MDA) section, and consolidated statements of profit or loss. While it is an announcement, it provides substantive financial data and analysis for the full fiscal year, which aligns with the definition of an Annual Report (10-K) or a comprehensive financial report. Given the structure and content, it serves as the primary annual financial disclosure for the company. FY 2024
2026-01-30 English
DATE OF BOARD MEETING
Report Publication Announcement Classification · 1% confidence The document is a formal announcement from Mega Genomics Limited stating that a board meeting will be held on 4 February 2026 to consider and approve the interim results and potential dividend. It does not contain the actual financial results or the report itself, but rather serves as a notification of the upcoming publication of these items. According to the 'Menu vs Meal' rule, an announcement regarding the timing or release of a report is classified as a Report Publication Announcement (RPA). H1 2025
2026-01-25 English
DATE OF BOARD MEETING
Earnings Release Classification · 1% confidence The document is a short announcement (1385 characters) from Mega Genomics Limited stating that a board meeting will be held on 30 January 2026 to consider and approve the final results for the year ended 31 December 2024. It does not contain the financial results themselves, but rather announces the date of the meeting where these results will be approved. This fits the definition of a Report Publication Announcement (RPA) or a general regulatory announcement regarding the timing of report releases. FY 2024
2026-01-20 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.